| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8071648 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
| US8324281 | NOVARTIS | Topical nepafenac formulations |
Dec, 2025
(2 years from now) | |
| US7834059 | NOVARTIS | Topical nepafenac formulations |
Jan, 2027
(3 years from now) | |
Nevanac is owned by Novartis.
Nevanac contains Nepafenac.
Nevanac has a total of 3 drug patents out of which 0 drug patents have expired.
Nevanac was authorised for market use on 19 August, 2005.
Nevanac is available in suspension/drops;ophthalmic dosage forms.
Nevanac can be used as method of treating ocular inflammation.
The generics of Nevanac are possible to be released after 31 January, 2027.
Drugs and Companies using NEPAFENAC ingredient
Market Authorisation Date: 19 August, 2005
Treatment: Method of treating ocular inflammation
Dosage: SUSPENSION/DROPS;OPHTHALMIC
NEVANAC family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic